Optimer slashes Dificid price to boost sales; New Merck packaging plant opens doors;

@FiercePharma: Will Optimer's plan to boost Dificid sales work? It's a volume-pricing move. More | Follow @FiercePharma

> Optimer Pharmaceuticals ($OPTR) said it would lower the price of its C. difficile fighter Dificid in a bid to boost sales to hospitals. Report

> Merck's ($MRK) Asia Pacific business opened a new $21 million packaging factory in East Java, Indonesia, where it will turn out packages for a variety of drugs, most for export. Report

> Ranbaxy Laboartories launched an authorized generic version of Evoxac, its parent Daiichi Sankyo's remedy for dry mouth in Sjoren's syndrome patients. Report

> The U.K.'s new drug-pricing mechanism will still include the sort of patient-access schemes--a.k.a. discounts--that boost a drug's chances of winning reimbursement. Report

> A Canadian study offered more evidence that children with egg allergies can be safely vaccinated against flu. Report

Medical Device News

 @FierceMedDev: Check out our rundown of the year's biggest announced layoffs in the medical device world. More | Follow @FierceMedDev

 @MarkHFierce: BD's CFO is leaving to pursue an "entrepreneurial opportunity." More | Follow @MarkHFierce

 @DamianFierce: Biomet reduced its quarterly losses thanks to its $280M buy of DePuy's trauma unit. More | Follow @DamianFierce

> Hospital transparency may be driving down stent use. Report

> Researchers: Concealing a stent with antibodies will prevent clots. Story

> Study: FDA, CMS device approval times still run long. Item

Biotech News

 @FierceBiotech: Diamyd Medical sells off nerve-targeted delivery unit. More | Follow @FierceBiotech

 @JohnCFierce: I'd like to see Lilly file an NDA on sola, see how regulators handle secondary analysis on data from 1 trial that couldn't be confirmed in 2nd. | Follow @JohnCFierce

 @RyanMFierce: Top counterfeit drug events in 2012 report, shows this problem affects all of us. More | Follow @RyanMFierce

> Gates Foundation jumps into $30M round for Genocea's T cell vaccines. News

> Pioneering study will test if trio of Roche, Lilly drugs can prevent Alzheimer's. Story

> MedImmune partners on trials for a new slate of cancer immunotherapy combos. Article

> Oxford Bio shares tumble after mid-stage cancer study fizzles out. News

Drug Delivery News

> NuPathe axes half its workforce, sells $28M of securities. Article

> Dissolving microneedles hit the sweet spot in diabetes. Item

> Diamyd Medical sells off nerve-targeted delivery unit. Story

> Smaller electric pulse hits the spot for DNA vaccines. Report

Biomarkers News

> Scratching a genetic itch in atopic dermatitis. More

> Biomarker panel spots the risk of Type 2 diabetes. Report

> Making a GENIE-us connection: Linking genes with diabetic kidney disease. Story

> Prostate cancer genetic barcodes predict aggressiveness. Article

And Finally... Pharmacists in Ontario, Canada, can now offer healthcare services, such as prescription renewals and flu shots, that might make up for revenue lost to falling drug prices. Report

Suggested Articles

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

By extending the tender offer for just six days, Roche seems confident it will receive positive reviews from U.S. and U.K. watchdogs in time.

Back in June, Takeda scrapped a Ninlaro trial in rare disease light-chain (AL) amyloidosis. Saturday, it shared the data behind the decision.